Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the Company).
On 31 December 2013, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2013; calculated using an average price of £16.07 per Ordinary Share and $53.17 per ADS:
Non-Executive Director |
Ordinary Shares |
No. of ADSs |
Sir Christopher Gent |
4,354.409 |
|
Prof Sir Roy Anderson |
675.908 |
|
Dr Stephanie Burns |
|
528.928 |
Stacey Cartwright |
125.486 |
|
Lynn Elsenhans |
|
62.813 |
Judy Lewent |
|
80.699 |
Sir Deryck Maughan |
|
1,343.402 |
Dr Daniel Podolsky |
|
951.863 |
Tom de Swaan |
980.751 |
|
Jing Ulrich |
|
19.485 |
Hans Wijers |
3.631 |
|
Sir Robert Wilson |
1,485.756 |
|
The Company and the Non-Executive Directors were informed of these allocations on 2 January 2014.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Sonja Arsenić
Corporate Secretariat
3 January 2014